Virpax Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRPX research report →
Range $3 – $3
Price Chart
About the company
Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addictive solutions for pain management, alongside therapies targeting central nervous system disorders.
- CEO
- Jatinder Dhaliwal
- IPO
- 2021
- Employees
- 2
- HQ
- Berwyn, PA, US
Get TickerSpark's AI analysis on VRPX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $249
- P/E
- -0.00
- Fwd P/E
- 0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.13
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -2364.82%
- ROIC
- 1322.00%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-12,079,935
- Net Income
- $-12,067,225+20.6%
- EPS
- $-70.91-446.7%
- OCF Growth
- -169509.2%
- FCF Growth
- -169509.2%
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 2.44
- RSI (14)
- 21
- Avg Volume
- 470
No earnings-call transcripts are available for VRPX yet.
- Free Float
- 84.8%
- Shares Outstanding
- 1.24M
- Float Shares
- 1.05M
of shares held by institutions
1 13F filers
Buy/sell ratio 9.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 17, 24 | Panis Jaydriane | other | 0 |
| Nov 18, 24 | Chaudhry Usama | other | 0 |
| Nov 19, 24 | Randhawa Esha | other | 0 |
| Jul 5, 24 | Su Judy | other | 0 |
| Jul 5, 24 | Field Katharyn | other | 2,500 |
| Jul 5, 24 | Field Katharyn | other | 0 |
| Jul 5, 24 | Herman Gary L | other | 2,500 |
| Jul 5, 24 | Dhaliwal Jatinder | other | 2,500 |
| Jul 5, 24 | Herman Gary L | other | 0 |
| Jul 5, 24 | Dhaliwal Jatinder | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VRPX coverage
Recent articles, reports, and earnings notes.
No research on VRPX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VRPX report →Reviewing Virpax Pharmaceuticals (NASDAQ:VRPX) and Zomedica (OTCMKTS:ZOMDF)
defenseworld.net · Apr 15
Financial Comparison: Virpax Pharmaceuticals (NASDAQ:VRPX) versus Merck KGaA (OTCMKTS:MKGAF)
defenseworld.net · Feb 1
Nabriva Therapeutics (NASDAQ:NBRV) versus Virpax Pharmaceuticals (NASDAQ:VRPX) Head-To-Head Contrast
defenseworld.net · Jan 3
Virpax Pharmaceuticals Announces Reverse Stock Split
businesswire.com · Mar 19
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND
businesswire.com · Mar 18
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
businesswire.com · Mar 7
Virpax's NES100 to be Presented at The Society of Toxicology by NCATS
businesswire.com · Mar 5
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate
benzinga.com · Feb 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.